Drug-permeability and transporter assays in Caco-2 and MDCK cell lines

Future Medicinal Chemistry

Volumn 3, Issue 16, 2011, Pages 2063-2077

  Volpe, Donna A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; CIPROFLOXACIN; CYCLOSPORIN; DIGOXIN; DIPYRIDAMOLE; ELACRIDAR; FLUINDOSTATIN; FUMITREMORGIN C; IBUPROFEN; IVERMECTIN; KETOCONAZOLE; LABETALOL; LAMIVUDINE PLUS ZIDOVUDINE; LEVOFLOXACIN; LOMEFLOXACIN; LORATADINE; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 5; OCTAMER TRANSCRIPTION FACTOR 2; OFLOXACIN; PEPTIDE TRANSPORTER 1; QUINIDINE; RIFAMPICIN; ROSUVASTATIN; SELAMECTIN; UNINDEXED DRUG; VERAPAMIL;

ARTIFICIAL MEMBRANE; ARTIFICIAL NEURAL NETWORK; AUTOMATION; CELL ASSAY; CELL PERMEABILIZATION; CELL STRAIN CACO 2; COMPUTER MODEL; CYTOTOXICITY; DRUG PENETRATION; DRUG TRANSPORT; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; MEMBRANE PERMEABILITY; MOLECULAR ELECTRONICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; CELL LINE, TUMOR; DOGS; HUMANS; PERMEABILITY; PHARMACOKINETICS;

EID: 81855206518     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.149     Document Type: Review

References (95)

1. Balimane PV, Han YH, Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 8(1), E1-E13 (2006).
2. Wang J, Skolnik S. Mitigating permeability-mediated risks in drug discovery. Expert Opin. Drug Metab. Toxicol. 6(2), 171-187 (2010).
3. Carlson TJ, Fisher MB. Recent advances in high-throughput screening for ADME properties. Comb. Chem. High Throughput Screen. 11(3), 258-264 (2008).
4. Wang J. Comprehensive assessment of ADMET risks in drug discovery. Curr. Pharm. Des. 15(19), 2195-2219 (2009).
5. Lennernäs H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 37(10-11), 1015-1051 (2007).
6. International Transporter Consortium. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9(3), 215-236 (2010).
7. Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica. 38(7-8), 709-724 (2008).
8. Thiel-Demby VE, Humphreys JE, St John Williams LA et al. Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. Mol. Pharm. 6(1), 11-18 (2009).
9. Volpe DA, Faustino PJ, Ciavarella AB et al. Classification of drug permeability with a Caco-2 cell monolayer assay. Clin. Res. Reg. Affairs 24(1), 39-47 (2007).
10. Stoner CL, Troutman M, Gao H et al. Moving in silico screening into practice: A minimalist approach to guide permeability screening! Lett. Drug Design Discov. 3(8), 575-581 (2006).
11. Skolnik S, Lin X, Wang J, Chen XH, He T, Zhang B. Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay. J. Pharm. Sci. 99(7), 3246-3265 (2010).
12. He Y, Liu Y, Zeng S. Stereoselective and multiple carrier-mediated transport of citerizine across Caco-2 cell monolayers with potential drug interaction. Chirality 22(7), 684-692 (2010).
13. Paixão P, Gouveia LF, Morais JA. Prediction of the in vitro permeability determined in Caco-2 cells by using artificial neural networks. Eur. J. Pharm. Sci. 41(1), 107-117 (2010).
14. Yan Z, Sun J, Chang Y et al. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics. Mol. Pharm. 8(2), 319-329 (2011).
15. Tsume Y, Vig BS, Sun J et al. Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters. Molecules 13(7), 1441-1454 (2008).
16. Bimbo LM, Mäkilä M, Laaksonen T et al. Drug permeation across intestinal epithelial cells using porous silicon nanoparticles. Biomaterials. 32(10), 2625-2633 (2011).
17. Kapitza SB, Michel BR, van Hoogevest P, Leigh MLS, Imanidis G. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model. Eur. J. Pharm. Biopharm. 66(1), 146-158 (2007).
18. Parmentier J, Hartmann FJ, Fricker G. In vitro evaluation of liposomes containing bio-enhancers for the oral delivery of macromolecules. Eur. J. Pharm. Biopharm. 76(3), 394-403 (2010).
19. Kowapradit J, Opanasopit P, Ngawhirunpat T et al. In vitro permeability enhancement in intestinal epithelial cells (Caco-2) monolayer of water soluble quaternary ammonium chitosan derivatives. AAPS PharmSci. Tech. 11(2), 497-508 (2010).
20. Omkvist DH, Brodin B, Nielsen CU. Ibuprofen is a non-competitive inhibitor of the peptide transporter hPEPT1 (SLC15A1): possible interactions between hPEPT1 substrates and ibuprofen. Brit. J. Pharmacol. 161(8), 1793-1805 (2010).
21. Neuhoff S, Ungell AL, Zamora I, Artursson P. pH dependent passive and active transport of acidic drugs across Caco-2 cell monolayers. Eur. J. Pharm. Sci. 25(2-3), 211-220 (2005).
22. Gertz M, Harrison A, Houston JB, Galetin A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos. 38(7), 1147-1158 (2010).
23. Berginc K, Žakelj S, Kristl A. In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. Eur. J. Nutr. 49(6), 373-384 (2010).
24. Han Y, Tan TMC, Lim LY. Effects of capsaicin on P-gp function and expression in Caco-2 cells. Biochem. Pharmacol. 71(12), 1727-1734 (2006).
25. Wang Q, Strab R, Kardos P et al. Application and limitation of inhibitors in 1 Balimane PV, Han YH, Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 8(1), E1-E13 (2006). drug-transporter interactions studies. Int. J. Pharm. 356(1-2), 12-18 (2008).
26. Volpe DA. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J. Pharm. Sci. 97(2), 712-725 (2008).
27. Elsby R, Surry DD, Smith VN, Gray AJ. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 38(7-8), 1140-1164 (2008).
28. Keogh JP, Kunta JR. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur. J. Pharm. Sci. 27 (5), 543-554 (2006).
29. Volpe DA. Application of method suitability for drug permeability classification. AAPS J. 12(4), 670-678 (2010).
30. Koljonen M, Hakala KS, Ahtola-Sätilä T et al. Evaluation of cocktail approach to standardise Caco-2 permeability experiments. Eur. J. Pharm. Biopharm. 64(3), 379-387 (2006).
31. Hidalgo IJ, Borchardt RT, Raub TJ. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96(3), 736-749 (1989).
32. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175(3), 880-885 (1991).
33. Artursson P, Tavelin S. Caco-2 and emerging alternatives for prediction of intestinal drug transport: A general overview. In: Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability. van de Waterbeem H, Lennernäs H (Eds), Wiley-VCH, Weinheim, Germany, Pages 72-89 (2003).
34. Sun D, Lennernäs H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, Amidon GL. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res. 19(10), 1400-1416 (2002).
35. Ranaldi G, Islam K, Sambuy Y. Epithelial cells in culture as a model for the intestinal transport of antimicrobial agents. Antimicrob. Agents Chemother. 36(7), 1374-1381 (1992).
36. Ranaldi G, Seneci P, Guba W, Islam K, Sambuy Y. Transport of the antibacterial agent oxazolidin-2-one and derivatives across intestinal (Caco-2) and renal (MDCK) epithelial cell lines. Antimicrob. Agents Chemother. 40(3), 652-658 (1996).
37. Irvine JD, Takahashi L, Lockhart K et al. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J. Pharm. Sci. 88(1), 28-33 (1999).
38. Zheng X, Diao L, Ekins, Polli JE. Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies. Biochem Pharmacol. 80(7), 1087-1092 (2011).
39. Hayeshi R, Hilgendorf C, Artursson P et al. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur. J. Pharm. Sci. 35(5), 383-396 (2008).
40. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungel AL, Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos. 35(8), 1333-1340 (2007).
41. Maubon N, Vee ML, Fossati L et al. Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR. Fund. Clin. Pharmacol. 21(6), 659-663 (2007).
42. Oostendorp RL, Beijnen JH, Schellens JHM. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat Rev. 35(2), 137-147 (2009).
43. Lam WK, Felmlee MA, Morris ME. Monocarboxylate transporter-mediated transport of g-hydroxybutyric acid in human intestinal Caco-2 cells. Drug Metab Dispos. 38(3), 441-447 (2010).
44. Englund G, Rorsman F, Rönnblom A et al. Regional levels of drug transporters along the human intestinal tract: Co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci. 29(3-4), 269-277 (2006).
45. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab. Dispos. 34(8) 1423-1431 (2006).
46. Li J, Zhang W, Allen SM et al. OATP expression in human intestinal epithelial cells and its influence on the transport of statin drugs across Caco-2 cell monolayers. Drug Metab. Rev. 41(Suppl. 3), 179-180 (2009).
47. Shirasaka Y, Konishi R, Funami N et al. Expression levels of human P-glycoprotein in in vitro cell lines: Correlation between mRNA and protein levels for P-glycoprotein expressed in cells. Biopharm. Drug Dispos. 30(3), 149-152 (2009).
48. Balimane PV, Chong S, Patel K et al. Peptide transporter substrate identification during permeability screening in drug discovery: Comparison of transfected MDCK-hPepT1 cells to Caco-2 Cells. Arch. Pharm. Res. 30(4), 507-518 (2007).
49. Horie A, Sakata J, Nishimura M, Ishida K, Taguchi M, Hashimoto Y. Mechanisms for membrane transport of metformin in human intestinal epithelial Caco-2 cells. Biopharm. Drug Dispos. 32(5), 253-260 (2011).
50. Ming X, Thakker DR . Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil. Biochem. Pharmacol. 79(3), 455-462 2010).
51. Xia CQ, Liu NL, Yang D, Miwa G, Gan LS. Expresion, localization and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab. Dispos. 33(5), 637-643 (2005).
52. Kis O, Zastre JA, Ramaswamy M, Bendayan R. pH dependence of OATP2B1 transporter in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J. Pharmacol. Exp. Ther. 334(3), 1009-1022 (2010).
53. Seithel A, Karlsson J, Hilgendorf C, Björquist, Ungell AL. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: Comparison between human segments and Caco-2 cells. Eur. J. Pharm. Sci. 28(4), 291-299 (2006).
54. Kamiyama E, Sugiyama D, Nakai D, Miura SI, Okazaki O. Culture period-dependent change of function and expression of ATP-Binding cassette transporters in Caco-2 cells. Drug Metab. Dispos. 37(9), 1956-1962 (2009).
55. Hunter J, Hirst BH, Simmons NL. Transepithelial secretion, cellular accumulation and cytotoxicity of vinblastine in defined MDCK cell strains. Biochim. Biophys. Acta. 1179(1), 1-10 (1993).
56. Shu Y, Bello CL, Mangravite LM, Feng B, Giacomini KM. Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells. J. Pharmacol. Exp. Ther. 299(1), 392-398 (2001).
57. Kuteykin-Teplyakov K, Luna-Tortós C, Ambroziak K, Löscher W. Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wild type cell lines affect P-glycoprotein mediated drug transport. Br. J. Pharmacol. 160(6), 1453-1463 (2010).
58. Putnam WS, Ramanathan S, Pan L, Takahashi LH, Benet LZ. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J. Pharm. Sci. 91(12), 2622-2635 (2002).
59. Tang F, Horie K, Borchardt RT. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm. Res. 19(6), 765-772 (2002).
60. Fenner KS, Troutman MD, Kempshall S et al. Drug-drug interactions mediated through P-glycoprotein: Clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin. Pharmacol. Ther. 85(2), 173-181 (2009).
61. Rautio J, Humphreys JE, Webster LO et al. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates. Drug Metab. Dispos. 34(5), 786-792 (2006).
62. Troutman MD, Thakker DR. Efflux ratio cannot assess P-glycoprotein- mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm. Res. 20(8), 1200-1209 (2003).
63. Balimane PV, Marino A, Chong S. P-gp inhibition potential in cell-based models: which 'calculation' method is the most accurate? AAPS J. 10, 577-586 (2008).
64. Volpe DA. Permeability classification of representative fluoroquinolones by a cell culture method. AAPS PharmSci. 6(2), e13 (2004).
65. de Souza J, Benet LZ, Huang Y, Storpirtis S. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1 and Caco-2 cell monolayers. J. Pharm. Sci. 98(11), 4413-4419 (2009).
66. Brayden DJ, Griffin J. Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers. Vet. Res. Commun. 32(1), 93-106 (2008).
67. Lin X, Skolnik S, Chen X, Wang J. Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. Drug Metab. Dispos. 39(2), 265-274 (2011).
68. Siissalo S, Hannukainen J, Kolehmainen J, Hirvonen J, Kaukonen AM. A Caco-2 cell based screening method for compounds interacting with MRP2 efflux protein. Eur. J. Pharm. Biopharm. 71(2), 332-338 (2009).
69. Förster F, Volz A, Fricker G. Compound profiling for ABCC2 (MRP2) using a fluorescent microplate system. Eur. J. Pharm. Biopharm. 69(1), 396-403 (2008).
70. Xiao Y, Davidson R, Smith A et al. A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCKII cell line. Mol. Pharm. 3(1), 45-54 (2006).
71. Graber-Maier A, Gutmann H, Drewe J. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib. Mol. Pharm. 7(5), 1618-1628 (2010).
72. Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40(3), 163-176 (2010).
73. Li J, Volpe DA, Wang Y et al. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab. Dispos. 39(7), 1196-1202 (2011).
74. Tamai I. Oral drug delivery utilizing intestinal OATP transporters. Adv. Drug Deliv. Rev. doi:10.1016/j.addr.2011.07.007 (2011) (In press).
75. Yeh TH, Hsu LW, Tseng MT et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials. 32(26), 6164-6173 (2011).
76. Zhu S, Huang R, Hong M, Jiang Y, Hu Z, Liu C, Pei Y. Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450. Eur. J. Pharm. Sci. 37(5), 573-580 (2009).
77. Hanke U, May K, Rozehnal V, Nagel S, Siegmund W, Weitschies W. Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2).Eur. J. Pharm. Sci. 76(2), 260-268 (2010).
78. Rais R, Fletcher S, Polli JE. Synthesis and in vitro evaluation of gabapentin prodrugs that target the human apical sodium-dependent bile acid transporter (hASBT).J. Pharm. Sci. 100(3), 1184-1195 (2011).
79. Zheng X, Polli JE. Synthesis and in vitro evaluation of potential sustained release prodrugs via targeting ASBT. Int. J. Pharm. 396(1-2), 111-118 (2010).
80. Cook JA, Feng B, Fenner KS et al. Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol. Pharm. 7(2), 398-411 (2010).
81. Collett A, Tanianis-Hughes J, Carlson GL, Harwood MD, Warhurst G. Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. Eur. J. Pharm. Sci. 26(5), 386-393 (2005).
82. Elsby R, Gillen M, Butters C et al. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: A case study for AZD5672. Drug Metab. Dispos. 39(2), 275-282 (2011).
83. Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J. Pharmacol. Sci. 113(4), 315-324 (2010).
84. Eberl S, Renner B, Neubert A et al. Role of P-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin. Pharmacokinet. 46(12), 1039-1049 (2007).
85. Kamiyama E, Nakai D, Mikkaichi T, Okudaira N, Okazaki O. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sci. 86(1-2), 52-58 (2010).
86. Masungi C, Mensch J, Van Dijck A et al. Parallel artificial membrane permeability assay (PAMPA) combined with a 10 day multiscreen Caco-2 cell culture as a tool for assessing new drug candidates. Pharmazie. 63(3), 194-199 (2008).
87. NoŽinić D, Milić A, Mikac L, Ralić J, Padovan J, Antolovic R. Assessment of macrolide transport using PAMPA, Caco-2 and MDCKII-hMDR1 assays. Croat. Chem. Acta. 83(3), 323-331 (2010).
88. Castillo-Garit JA, Marrero-Ponce Y, Torrens F, García-Domenech R. Estimation of ADME properties in drug discovery: predicting Caco-2 cell permeability using atom-based stochastic and non-stochastic linear indices. J. Pharm. Sci. 97(5), 1946-1976 (2008).
89. Stoner CL, Troutman M, Gao H et al. Moving in silico screening into practice: A minimalist approach to guide permeability screening! Lett. Drug Design Discov. 3(8), 575-581 (2006).
90. Peters SA. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin. Pharmacokinet. 47(4), 261-275 (2008).
91. Lai Y, Sampson KE, Stevens JC. Evaluation of drug transporter interactions in drug discovery and development. Comb. Chem. High Throughput Screen. 13(2), 112-134 (2010).
92. Shin HJ, Lee CH, Park SJ, Shin JG, Song IS. Establishment and characterization of Madin-Darby canine kidney cells stably expressing human organic anion transporters. Arch. Pharm. Res. 33(5), 709-716 (2010).
93. Hakkarainen JJ, Jalkanen AJ, Kääriäinen TM et al. Comparison of in vitro cell models in predicting in vivo brain entry of drugs. Int. J. Pharm. 402(1-2), 27-36 (2010).
94. Kwatra D, Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK. Interaction of gatifloxacin with efflux transporters: A possible mechanism for drug resistance. Int. J. Pharm. 395(1-2), 114-121 (2010).
95. Sugano K. Fraction of a dose absorbed estimation for structurally diverse low solubility compounds. Int. J. Pharm. 405(1-2), 79-89 (2011).